2Mountantonakis SE, Moutzouris DA, Tiu RV, et al. Ibutilide to ex- pedite ED therapy for recent - onset atrial fibrillation flutter[ J ]. Am J Emerg Med ,2006,24(4) :407 -412.
3VOS M A, GOLITSYN S R, STANGL K, et al. Superiority of Ibutilide (a newclass Ⅲ agent) over DL- sotalol in converting atrial flutter and atrial fibrillation [J]. Heart,1998,79:568-575.
4STAMBLER B S, WOOD M A, ELLENBOGEN K A, et al. Antiarrhymicactions of intravenous Ibutilide compared with procaimamide during human atrial flutter and fibrillation: Electrophysilogical determinants of enhanced conversion efficacy[J]. Circulation,1997, 96:4298-4306.
5GOWDA R M, KHAN I A, SABRINA L, et al. Torsade de pointes: the clinical considerations [JJ. Int J Cardiol, 2004,96 : 1 - 6.
6QUNAN X Q, ZHANG C T, BAI R, et al. Increasing gap junction coupling reduces transmural dispersion of repolarization and prevents torsade de pointes in rabbit LQT3 model[J]. J Cardiovascular Electrophysiol, 2007,18:1184- 1189.
7YANG T, SNYDERS D, RODEN D M. Drug block of I (kr) : model systems and relevance to human arrhythmias [J]. J Cardiovasc Pharmacol, 2001,38 : 737- 744,.
8LEE K S. Ibutilide, a new compound with potent class Ⅲ antiarrhythmic activity, activates a slow inward Na^+ current in guinea pig ventrieular cells[J].J Pharmacol Exp Ther, 1992,262 :99- 108.
9ANDO G, DIROSA S, RIZZO F, et al. Ihutilide for cardioversion of atrial flutter: efficacy of a single dose in recent onset arrhythmias[J]. Minerva Cardioangiol,2004,52:37-42.
10ORAL H, SOUZA J J, MICHAUD G F, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment [J]. N Engl J Med,1999, 340:1849-1854.
